background: dendritic cells (dcs) are professional antigen presenting cells (apcs), and there is considerable interest in their application as a cellular adjuvant for cancer immunotherapy.  previous studies indirectly demonstrated that dcs were able to take up tumor lysate (crude soluble tumor antigens) and also cross-present tumor associated antigens (taa) which elicits anti-tumor immune respo...

Cancer immunotherapy has gained a lot of interest over the past few years due to the success of immune checkpoint inhibitors in treating cancer (1, 2). Immune checkpoint inhibitors, such as monoclonal antibodies against cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) and programmed death 1 (PD-1), have been shown to increase survival of patients with advanced cancers (1, 2). These in...

Cancer immunotherapy has gained a lot of interest over the past few years due to the success of immune checkpoint inhibitors in treating cancer (1, 2). Immune checkpoint inhibitors, such as monoclonal antibodies against cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) and programmed death 1 (PD-1), have been shown to increase survival of patients with advanced cancers (1, 2). These in...

Introduction: Binding a monoclonal antibody to tumor associated antigens is an effective method for cancer therapy because these agents can specifically target malignant cells, in fact monoclonal antibodies are effective agents for diagnosis, grading and treatment of different kinds of cancers. Methods: In this research, a new monoclonal antibody against colon cancer cells was prepared an...